Bienvenue sur le forum TechNet

WHO recommends 2 temperature ranges for keeping all vaccines at health facilities (+2C +8C) and (-15C -25C) for OPV above district level. The rationale for using first range is explained in “Thermostability of vaccines”. What is the reason for use of second range (-15C -25C) for OPV and some freez...

We are pleased to share the new PtD Newsflash no. 16 with our colleagues.     In this issue of the PtD Newsflash, read more about the: Webinar for the LAC region on systematic approaches to increasing professionalism in health SCM Newgraduates from the Pharmacy Assistant Training...

Dear Colleagues, Thank you to those who filled in the 1st and 2nd survey. We have had over 110 responses so far. We still need your help with the last survey. As part of the GAVI supply chain strategy PtD has been leading the development of a ‘SCM Leadership Competency Framework’ as part of the...

Dear Friends, I must congratulate the GAVI board for taking a decision on introducing IPV. I hope the IPV would be introduced through cost effective intra-dermal method by enhancing its antigenic content and also through cost effective disposable syringe and needle method. Also the decision for inc...

The Indian government suspended research in April 2010 on the feasibility and safety of human papillomavirus (HPV) vaccine in two Indian states (Andhra Pradesh and Gujarat) amid public concerns about its safety. This paper describes cervical cancer and cancer surveillance in India and reviews the ep...

This is not a new thing. After delivery requesting for an early discharge is a common high risk practice. There is a rising awareness among the community, thanks to social mobilization by the ASHA and the Govt for introducing "ASHA" who accompanies the precious pregnant women who deliver the future ...

In late 90's we are hearing about '0' OPV . To start with '0' meant one which is not entered in the immunization card. It can be administered on the day of birth ( 0 day) or within 2 weeks so that there will be a gap of 4 weeks between the 2 drops of potent OPV given in this period and the first dos...

In collaboration with Merck & Co., Inc. and GSK, PATH Seattle has prepared a list of countries where each of these company's vaccines is licensed and a world map showing the countries where one of the vaccines is licensed for use and the countries where both vaccines are licensed for use. These ...

This message has been cross-posted from HPV Vaccine Global Community of Practice. With many thanks to Robert Steinglass. Dear Lisa, I agree with Sarah Mullins that there is a great opportunity to find links with a larger package of interventions, including tetanus vaccination. The following four r...

Dear Sir,Based on the PATH report, we must immediately demand from DCGI office or GOI for use of IPV through Intradermal Route as well, otherwise people would be cheated as they have been with Rabies vaccine. Though I disagree with the report on one point that is a device is required for effective d...

POST 00713E : INTRODUCING TT UNIJECT 3 September 2004 Jessica Fleming (mailto:[email protected]) from PATH informs us that the final "Introducing TT Uniject" guide for program planners is now available for download from PATH site at :   http://www.path.org/materials/materials-details.php?id=9...

Post00253 UNIJECT UPDATE 23 May 2000 CONTENTS 1. UNIJECT UPDATE UNIJECT UPDATE Debbie Kristensen, PATH, has kindly posted an update on the UNIJECT a proprietary, auto-disable, prefilled device. It combines drug or biological, syringe, and needle packaged in a sealed foil pouch. UNIJECT te...